Navegando por Autor "Ferreira, Rafaela Salgado"

Agora exibindo 1 - 2 de 2

Antimetastatic effect of the pharmacological inhibition of serine/arginine-rich protein kinases (SRPK) in murine melanoma
(Toxicology and Applied Pharmacology, 2018-10-01) Moreira, Gabriela Alves; Lima, Graziela Domingues de Almeida; Siqueira, Raoni Pais; Barros, Marcus Vinícius de Andrade; Adjanohoun, Abraham Landry Mahuvi; Santos, Viviane Corrêa; Barbosa, Éverton de Almeida Alves; Loterio, Robson Kriiger; Paiva, Janine Cerqueira de; Gonçalves, Victor Hugo Sousa; Viol, Lívia Cristina de Souza; Marques-da-Silva, Eduardo de Almeida; Silva Júnior, Abelardo; Almeida, Márcia Rogéria; Fietto, Juliana Lopes Rangel; Machado-Neves, Mariana; Ferreira, Rafaela Salgado; et al.
The Serine/arginine-rich protein kinases (SRPK) are involved in pre-mRNA splicing control through the phosphorylation of the SR protein family of splicing factors. Over the last years, several studies have shown the relevance of SRPK for human cancers and their potential as promising drug targets. In this context, we have previously selected three trifluoromethyl arylamides (named here as SRVIC24, SRVIC30 and SRVIC36) with improved in vitro antileukemia effect and ability of impairing the cellular activity of SRPK. Given the increasing amount of reports on the implication of these kinases in metastatic cancers, in this study, we have evaluated the antimetastatic effect of these compounds and the known SRPK inhibitor (SRPIN340) on a murine model of metastatic melanoma. The compounds were able to impact the melanoma cell metastatic behavior by decreasing migration, invasion, adhesion, and colony formation in in vitro assays. Also, they presented antimetastatic in vivo activity, without apparent signs of systemic toxicity after treatments, as revealed by the histology of organs and analysis of key serum biochemical markers. Moreover, the effect of the treatments on SRPK1 nuclear translocation and SR protein phosphorylation was observed. Finally, molecular docking studies were carried out to gain structural information on the SRPK-compound complexes. Together, these data suggest that SRPK pharmacological inhibition should be considered as an interesting therapeutic strategy against metastatic cancers.
Synthesis and leishmanicidal activity of eugenol derivatives bearing 1,2,3-triazole functionalities
(European Journal of Medicinal Chemistry, 2018-01-15) Teixeira, Róbson Ricardo; Gazolla, Poliana Aparecida Rodrigues; Silva, Adalberto Manoel da; Borsodi, Maria Paula Gonçalves; Bergmann, Bartira Rossi; Ferreira, Rafaela Salgado; Vaz, Boniek Gontijo; Vasconcelos, Géssica Adriana; Lima, Wallace Pacienza
In this paper, it is described the synthesis and the evaluation of the leishmanicidal activity of twenty-six eugenol derivatives bearing 1,2,3-triazole functionalities. The evaluation of the compounds on promastigotes of Leishmania amazonensis (WHOM/BR/75/Josefa) showed that eugenol derivatives present leishmanicidal activities with varying degrees of effectiveness. The most active compound, namely 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-methylbenzyl)-1H-1,2,3-triazole (7k) (IC50 = 7.4 ± 0.8 μmol L−1), also targeted Leishmania parasites inside peritoneal macrophages (IC50 = 1.6 μmol L−1) without interfering with cell viability. The cytotoxicity of 7k against macrophage cells presented IC50 of 211.9 μmol L−1 and the selective index was equal to 132.5. Under similar conditions, compound 7k was more effective than glucantime and pentamidine, two drugs currently in the clinic. In addition, theoretical calculations showed that this compound also presents most physicochemical and pharmacokinetic properties within the ranges expected for orally available drugs. It is believed that eugenol bearing 1,2,3-triazole functionalities may represent a scaffold to be explored toward the development of new agents to treat leishmaniasis.